Pub Date : 2026-01-26DOI: 10.1038/s41582-026-01184-0
Anny Reyes, Robyn M. Busch, Elaine T. Kiriakopoulos, Temitayo Oyegbile-Chidi, Bruce P. Hermann
{"title":"The role of social context in cognitive and neurobehavioural outcomes in epilepsy","authors":"Anny Reyes, Robyn M. Busch, Elaine T. Kiriakopoulos, Temitayo Oyegbile-Chidi, Bruce P. Hermann","doi":"10.1038/s41582-026-01184-0","DOIUrl":"https://doi.org/10.1038/s41582-026-01184-0","url":null,"abstract":"","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"31 4 1","pages":""},"PeriodicalIF":38.1,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146048258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-16DOI: 10.1038/s41582-025-01173-9
Harriet Demnitz-King, Sube Banerjee, Claudia Cooper, Charlotte Kenten, Rosemary Phillips, Sedigheh Zabihi, Yvonne Birks, Carol Brayne, Sallyann Browning, Camille Carroll, Georgina Charlesworth, Carol AC Coupland, Tom Dening, Ruth Dobson, Isabelle F. Foote, Sarah Foster, Chris Fox, Robert Howard, Jeremy D. Isaacs, Uzma Jaffry, Ivan Koychev, Gill Livingston, David J. Llewellyn, Richard Oakley, Magdalena Opazo Bretón, Martin Orrell, Alastair J. Noyce, Tommy Pouncey, Greta Rait, Janice Ranson, Mohammed Rauf, Vanessa Raymont, Elizabeth L. Sampson, Jonathan M. Schott, Debs Smith, Xin You Tai, Alison Thomson, Sebastian Walsh, Dylan M. Williams, Naaheed Mukadam, Charles R. Marshall, on behalf of The National Institute of Health and Care Research Policy Research Unit in Dementia and Neurodegeneration at Queen Mary University of London (DeNPRU-QM)
Translation of evidence about dementia risk and its reduction into effective, equitable public health policy is a major challenge. To address this challenge, the National Institute for Health and Care Research Policy Research Unit in Dementia and Neurodegeneration at Queen Mary University of London (DeNPRU-QM) convened a multidisciplinary panel of 40 experts from across England, with diverse lived, academic, clinical, policy and advocacy experience, at various career stages, and of diverse gender and ethnicity, to develop actionable policy recommendations for dementia risk reduction. Through a 2-day in-person workshop and a subsequent three-round modified Delphi survey, the panel evaluated and refined statements on dementia prevention. The panel achieved consensus on 56 recommendations in four domains: public health messaging, individual-level interventions, population-level interventions and research commissioning. A key priority across all domains was the need to consider and address health inequalities so that prevention efforts do not exacerbate existing disparities. Our recommendations provide policymakers with a robust foundation for designing and implementing an evidence-based dementia prevention strategy in England and provide guidance that can inform approaches in other countries and contexts. By prioritizing clear communication, targeted intervention and sustained research investment, the recommendations can help to address structural inequities and advance dementia risk reduction. Ongoing cross-sector advocacy will be crucial in driving policy adoption and implementation. Translation of evidence about dementia risk into effective public health policy is a challenge. In this Consensus Statement, Demnitz-King and colleagues present 56 policy recommendations for dementia prevention, providing policymakers with a foundation for designing and implementing evidence-based dementia prevention strategies, prioritizing clear communication, targeted intervention and sustained research investment.
{"title":"The Nottingham consensus on dementia risk reduction policy: recommendations from a modified Delphi process","authors":"Harriet Demnitz-King, Sube Banerjee, Claudia Cooper, Charlotte Kenten, Rosemary Phillips, Sedigheh Zabihi, Yvonne Birks, Carol Brayne, Sallyann Browning, Camille Carroll, Georgina Charlesworth, Carol AC Coupland, Tom Dening, Ruth Dobson, Isabelle F. Foote, Sarah Foster, Chris Fox, Robert Howard, Jeremy D. Isaacs, Uzma Jaffry, Ivan Koychev, Gill Livingston, David J. Llewellyn, Richard Oakley, Magdalena Opazo Bretón, Martin Orrell, Alastair J. Noyce, Tommy Pouncey, Greta Rait, Janice Ranson, Mohammed Rauf, Vanessa Raymont, Elizabeth L. Sampson, Jonathan M. Schott, Debs Smith, Xin You Tai, Alison Thomson, Sebastian Walsh, Dylan M. Williams, Naaheed Mukadam, Charles R. Marshall, on behalf of The National Institute of Health and Care Research Policy Research Unit in Dementia and Neurodegeneration at Queen Mary University of London (DeNPRU-QM)","doi":"10.1038/s41582-025-01173-9","DOIUrl":"10.1038/s41582-025-01173-9","url":null,"abstract":"Translation of evidence about dementia risk and its reduction into effective, equitable public health policy is a major challenge. To address this challenge, the National Institute for Health and Care Research Policy Research Unit in Dementia and Neurodegeneration at Queen Mary University of London (DeNPRU-QM) convened a multidisciplinary panel of 40 experts from across England, with diverse lived, academic, clinical, policy and advocacy experience, at various career stages, and of diverse gender and ethnicity, to develop actionable policy recommendations for dementia risk reduction. Through a 2-day in-person workshop and a subsequent three-round modified Delphi survey, the panel evaluated and refined statements on dementia prevention. The panel achieved consensus on 56 recommendations in four domains: public health messaging, individual-level interventions, population-level interventions and research commissioning. A key priority across all domains was the need to consider and address health inequalities so that prevention efforts do not exacerbate existing disparities. Our recommendations provide policymakers with a robust foundation for designing and implementing an evidence-based dementia prevention strategy in England and provide guidance that can inform approaches in other countries and contexts. By prioritizing clear communication, targeted intervention and sustained research investment, the recommendations can help to address structural inequities and advance dementia risk reduction. Ongoing cross-sector advocacy will be crucial in driving policy adoption and implementation. Translation of evidence about dementia risk into effective public health policy is a challenge. In this Consensus Statement, Demnitz-King and colleagues present 56 policy recommendations for dementia prevention, providing policymakers with a foundation for designing and implementing evidence-based dementia prevention strategies, prioritizing clear communication, targeted intervention and sustained research investment.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 2","pages":"123-135"},"PeriodicalIF":33.1,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41582-025-01173-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145986556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-09DOI: 10.1038/s41582-025-01179-3
Moran Gilat,Jorik Nonnekes,Stewart A Factor,Bastiaan R Bloem,John G Nutt,Nir Giladi,Mark Hallett,Alice Nieuwboer,Fay B Horak,Daniel Weiss,Esther Cubo,Demi Zoetewei,Caroline Moreau,Beomseok Jeon,Tuhin Virmani,Jeffrey M Hausdorff,Alfonso Fasano,Simon J G Lewis,
Freezing of gait (FOG) is among the most debilitating symptoms of Parkinson disease and related disorders, often resulting in falls and a loss of independence. FOG has an episodic and heterogeneous nature that makes it difficult to measure and treat. The field currently lacks a consensus on how to precisely define this phenomenon. For this reason, the International Consortium for Freezing of Gait convened a group of experts to establish an updated 'clinical' definition of FOG for use in the clinical setting and a 'technical' definition for assessors to use when scoring FOG episodes from video recordings as an outcome in fundamental research and clinical trials. Guidelines on how to classify people with Parkinson disease into subgroups of those with or without FOG (non-FOG) are also provided. This position paper presents these new definitions and guidelines, offering a foundation for harmonizing the study and management of FOG.
{"title":"An updated definition of freezing of gait.","authors":"Moran Gilat,Jorik Nonnekes,Stewart A Factor,Bastiaan R Bloem,John G Nutt,Nir Giladi,Mark Hallett,Alice Nieuwboer,Fay B Horak,Daniel Weiss,Esther Cubo,Demi Zoetewei,Caroline Moreau,Beomseok Jeon,Tuhin Virmani,Jeffrey M Hausdorff,Alfonso Fasano,Simon J G Lewis, ","doi":"10.1038/s41582-025-01179-3","DOIUrl":"https://doi.org/10.1038/s41582-025-01179-3","url":null,"abstract":"Freezing of gait (FOG) is among the most debilitating symptoms of Parkinson disease and related disorders, often resulting in falls and a loss of independence. FOG has an episodic and heterogeneous nature that makes it difficult to measure and treat. The field currently lacks a consensus on how to precisely define this phenomenon. For this reason, the International Consortium for Freezing of Gait convened a group of experts to establish an updated 'clinical' definition of FOG for use in the clinical setting and a 'technical' definition for assessors to use when scoring FOG episodes from video recordings as an outcome in fundamental research and clinical trials. Guidelines on how to classify people with Parkinson disease into subgroups of those with or without FOG (non-FOG) are also provided. This position paper presents these new definitions and guidelines, offering a foundation for harmonizing the study and management of FOG.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"15 1","pages":""},"PeriodicalIF":38.1,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145937845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1038/s41582-025-01177-5
Mie Rizig, Mohamed Salama
Emerging genomic studies across Africa are revealing how decades of population bias have constrained understanding of disease mechanisms. New evidence in Parkinson disease genetics illustrates how overlooking Africa’s vast genetic diversity not only limits scientific insight but also slows the development of medical and biotechnological innovations that are vital for advancing global health.
{"title":"Genetic insights from Parkinson disease in African and African admixed populations","authors":"Mie Rizig, Mohamed Salama","doi":"10.1038/s41582-025-01177-5","DOIUrl":"10.1038/s41582-025-01177-5","url":null,"abstract":"Emerging genomic studies across Africa are revealing how decades of population bias have constrained understanding of disease mechanisms. New evidence in Parkinson disease genetics illustrates how overlooking Africa’s vast genetic diversity not only limits scientific insight but also slows the development of medical and biotechnological innovations that are vital for advancing global health.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 2","pages":"71-72"},"PeriodicalIF":33.1,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145889797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-12DOI: 10.1038/s41582-025-01172-w
Felicia C. Chow, Julia Granerod, Carla Y. Kim, Temesgen Nurye, Kiran T. Thakur
Vaccination is widely considered to be the pre-eminent public health achievement of modern history, but declining coverage resulting from vaccine hesitancy and from interruptions in immunization campaigns in geopolitically unstable regions threatens progress against vaccine-preventable diseases. The global burden of vaccine-preventable neurological diseases is substantial, resulting in acute and chronic complications as well as high case fatality rates. In recent years, outbreaks of dengue, poliomyelitis, measles, pertussis, meningococcal disease and Japanese encephalitis virus have been linked to lack of access to vaccines, overwhelmed health-care systems, misinformation and disinformation regarding vaccine safety, and gaps in vaccination coverage caused by environmental factors and geopolitical conflicts. Coordinated global strategies, including addressing barriers to vaccination and ensuring equitable access; targeted health education about vaccine benefits and risks; integration with other public services; and advances in next-generation vaccine technologies to tackle antimicrobial resistance and non-vaccine serotype replacement, will be crucial to prevent a resurgence of vaccine-preventable neurological diseases, especially in vulnerable populations, to maintain global health security. We are witnessing a worldwide resurgence in vaccine-preventable neurological diseases owing to gaps in vaccination coverage caused by multiple factors, including vaccine hesitancy and geopolitical conflicts. This Review highlights ongoing challenges to controlling vaccine-preventable neurological diseases such as measles, poliomyelitis, Japanese encephalitis and meningitis and considers how collaborative global strategies can facilitate effective immunization policies.
{"title":"The global threat of vaccine-preventable neurological diseases","authors":"Felicia C. Chow, Julia Granerod, Carla Y. Kim, Temesgen Nurye, Kiran T. Thakur","doi":"10.1038/s41582-025-01172-w","DOIUrl":"10.1038/s41582-025-01172-w","url":null,"abstract":"Vaccination is widely considered to be the pre-eminent public health achievement of modern history, but declining coverage resulting from vaccine hesitancy and from interruptions in immunization campaigns in geopolitically unstable regions threatens progress against vaccine-preventable diseases. The global burden of vaccine-preventable neurological diseases is substantial, resulting in acute and chronic complications as well as high case fatality rates. In recent years, outbreaks of dengue, poliomyelitis, measles, pertussis, meningococcal disease and Japanese encephalitis virus have been linked to lack of access to vaccines, overwhelmed health-care systems, misinformation and disinformation regarding vaccine safety, and gaps in vaccination coverage caused by environmental factors and geopolitical conflicts. Coordinated global strategies, including addressing barriers to vaccination and ensuring equitable access; targeted health education about vaccine benefits and risks; integration with other public services; and advances in next-generation vaccine technologies to tackle antimicrobial resistance and non-vaccine serotype replacement, will be crucial to prevent a resurgence of vaccine-preventable neurological diseases, especially in vulnerable populations, to maintain global health security. We are witnessing a worldwide resurgence in vaccine-preventable neurological diseases owing to gaps in vaccination coverage caused by multiple factors, including vaccine hesitancy and geopolitical conflicts. This Review highlights ongoing challenges to controlling vaccine-preventable neurological diseases such as measles, poliomyelitis, Japanese encephalitis and meningitis and considers how collaborative global strategies can facilitate effective immunization policies.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 2","pages":"110-122"},"PeriodicalIF":33.1,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145732741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-10DOI: 10.1038/s41582-025-01178-4
Ian Fyfe
Loss of TDP43 from the nucleus in amyotrophic lateral sclerosis and frontemporal dementia leads to changes in polyadenylation that alter mRNA processing, according to new research.
{"title":"RNA polyadenylation altered by TDP43 loss of function","authors":"Ian Fyfe","doi":"10.1038/s41582-025-01178-4","DOIUrl":"10.1038/s41582-025-01178-4","url":null,"abstract":"Loss of TDP43 from the nucleus in amyotrophic lateral sclerosis and frontemporal dementia leads to changes in polyadenylation that alter mRNA processing, according to new research.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 1","pages":"3-3"},"PeriodicalIF":33.1,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145717570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-08DOI: 10.1038/s41582-025-01174-8
Heather Wood
A new study indicates that physical activity reduces cognitive decline, possibly through attenuation of tau accumulation in the brain.
一项新的研究表明，体育活动可以减少认知能力的下降，可能是通过减少大脑中tau蛋白的积累。
{"title":"Physical activity could protect against cognitive decline","authors":"Heather Wood","doi":"10.1038/s41582-025-01174-8","DOIUrl":"10.1038/s41582-025-01174-8","url":null,"abstract":"A new study indicates that physical activity reduces cognitive decline, possibly through attenuation of tau accumulation in the brain.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 1","pages":"4-4"},"PeriodicalIF":33.1,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145704364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-08DOI: 10.1038/s41582-025-01176-6
Heather Wood
Recent research indicates that the brain-first and body-first subtypes of Parkinson disease can be distinguished by patterns of cutaneous α-synuclein deposition.
最近的研究表明，帕金森病的脑优先亚型和体优先亚型可以通过皮肤α-突触核蛋白沉积模式来区分。
{"title":"α-Synuclein signatures mark Parkinson disease subtypes","authors":"Heather Wood","doi":"10.1038/s41582-025-01176-6","DOIUrl":"10.1038/s41582-025-01176-6","url":null,"abstract":"Recent research indicates that the brain-first and body-first subtypes of Parkinson disease can be distinguished by patterns of cutaneous α-synuclein deposition.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 1","pages":"4-4"},"PeriodicalIF":33.1,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145704363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-08DOI: 10.1038/s41582-025-01175-7
Heather Wood
A drug that targets lysosomal damage could boost the effects of gene therapy for Duchenne muscular dystrophy, according to new research.
一项新的研究表明，一种针对溶酶体损伤的药物可能会提高杜氏肌营养不良症基因治疗的效果。
{"title":"Targeting lysosomal damage in Duchenne muscular dystrophy","authors":"Heather Wood","doi":"10.1038/s41582-025-01175-7","DOIUrl":"10.1038/s41582-025-01175-7","url":null,"abstract":"A drug that targets lysosomal damage could boost the effects of gene therapy for Duchenne muscular dystrophy, according to new research.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 1","pages":"4-4"},"PeriodicalIF":33.1,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145704365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-05DOI: 10.1038/s41582-025-01171-x
Linda Douw, Jaap C. Reijneveld, Ayan S. Mandal
Adult glioma is associated with a wide range of symptoms and variable survival that are not fully explained by tumour location or subtype. Recent work suggests that the disease may be better understood using a network-based framework, as opposed to more traditional localizationist thinking. In this Review, we describe three major types of network scaffolds relevant in people with glioma: symptom networks, the connectome and tumour biology networks. We summarize current evidence on how symptoms co-occur to form patterns, how gliomas affect structural and functional brain connectivity beyond the lesion and how tumour cells form intricate networks that interact with their surroundings. We then explore the relationships between local and global perspectives within each scaffold, and how these three scaffolds are interrelated, for example, through associations among tumour connectivity, cognitive performance and survival. We examine how current treatments such as surgery, radiotherapy, chemotherapy and anti-seizure medication interact with various network scaffolds. Group-level findings often do not reflect individual variability, and we highlight the need for personalized, longitudinal, multimodal and standardized network studies. Finally, we outline future steps towards integration of these three, and potentially additional network scaffolds, to provide network-informed care to patients with glioma. Emerging evidence suggests that a better understanding of the heterogeneity in symptoms and survival among people with glioma requires a network-based approach. This Review describes three major types of network scaffolds relevant in glioma — symptom networks, the connectome and tumour biology networks — and explores the interactions between each scaffold.
{"title":"Multiscale network perspectives on glioma: from tumour biology to symptoms, survival and treatment","authors":"Linda Douw, Jaap C. Reijneveld, Ayan S. Mandal","doi":"10.1038/s41582-025-01171-x","DOIUrl":"10.1038/s41582-025-01171-x","url":null,"abstract":"Adult glioma is associated with a wide range of symptoms and variable survival that are not fully explained by tumour location or subtype. Recent work suggests that the disease may be better understood using a network-based framework, as opposed to more traditional localizationist thinking. In this Review, we describe three major types of network scaffolds relevant in people with glioma: symptom networks, the connectome and tumour biology networks. We summarize current evidence on how symptoms co-occur to form patterns, how gliomas affect structural and functional brain connectivity beyond the lesion and how tumour cells form intricate networks that interact with their surroundings. We then explore the relationships between local and global perspectives within each scaffold, and how these three scaffolds are interrelated, for example, through associations among tumour connectivity, cognitive performance and survival. We examine how current treatments such as surgery, radiotherapy, chemotherapy and anti-seizure medication interact with various network scaffolds. Group-level findings often do not reflect individual variability, and we highlight the need for personalized, longitudinal, multimodal and standardized network studies. Finally, we outline future steps towards integration of these three, and potentially additional network scaffolds, to provide network-informed care to patients with glioma. Emerging evidence suggests that a better understanding of the heterogeneity in symptoms and survival among people with glioma requires a network-based approach. This Review describes three major types of network scaffolds relevant in glioma — symptom networks, the connectome and tumour biology networks — and explores the interactions between each scaffold.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 2","pages":"73-89"},"PeriodicalIF":33.1,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145680155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：